What is the 13F Pro Quality Score for AVTX?

13F Pro ranks Avalo Therapeutics, Inc. (AVTX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AVTX's current score at https://13fpro.ai/research/AVTX (free sign-up required for the full ranking).

Which hedge funds own the most AVTX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of AVTX include FMR, Caligan Partners, BVF /IL. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/AVTX as soon as new 13F filings post.

Where does 13F Pro source AVTX data?

All Avalo Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Avalo Therapeutics, Inc. files with the SEC under CIK 1534120. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AVTX in?

Avalo Therapeutics, Inc. (AVTX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is AVTX research updated on 13F Pro?

AVTX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Avalo Therapeutics, Inc.(AVTX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1534120 AVTX stock profile & AI dashboard →

13F Pro Quality Score

4.6/100

Rank #2,852 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

1.1/100

Profitability

0.4/100

Balance Sheet

1.6/100

Earnings Quality

30.0/100

Free Cash Flow

0.4/100

Institutional Flow

48.6/100

Revenue Scale

0.4/100

Dilution Risk

0.1/100

AVTX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Avalo Therapeutics, Inc. (AVTX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AVTX at 4.6/100 on a 32-signal composite quality model, placing it at rank #2,852 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (0.4) and free cash flow (0.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Avalo Therapeutics, Inc. reports net income of $-19.6M, free cash flow of $-17.7M. Top institutional holders of AVTX by reported 13-F value include FMR, Caligan Partners, BVF /IL, based on the most recent SEC filings. AVTX trades on the Nasdaq exchange and files with the SEC under CIK 1534120. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AVTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Avalo Therapeutics, Inc. directly from SEC EDGAR. Avalo Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 4 and 37 since 2025, currently 4.6 — a declining long-term trajectory across 12 quarterly and live scoring snapshots.

✦

Fun facts about Avalo Therapeutics, Inc.

Quirks, history, and lore behind AVTX — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Maryland · focused on treatments for rare and serious diseases.
2
The Numbers
A micro-cap with minimal revenue — like most clinical-stage biotechs, it runs on cash reserves and equity raises while its pipeline matures toward potential approval.
3
The History
The company has undergone significant strategic pivots over the years, narrowing its focus and restructuring its pipeline as it chased the most promising therapeutic targets.
4
The Secret
Its pipeline has centered on immunology and inflammation, targeting conditions driven by complement system dysregulation — a notoriously tricky but high-value corner of biology.
5
The Lore
The company's name nods to avalanche imagery — a fitting metaphor for the cascade of immune reactions it hopes its drugs can stop in their tracks.
6
The Giveaway
Trading under the ticker AVTX, this is Avalo Therapeutics — a small Maryland biotech swinging at rare immune diseases one clinical trial at a time.

▶ Think you know your stocks? Play the Daily Ticker

Net Income

Q1 2026

$-19.6M

Free Cash Flow

Q1 2026

$-17.7M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-86.6% YoY

$59.0KFY 2025

FY21 $5.4MFY22 $18.1MFY24 $441.0KFY25 $59.0K

Net Income

-122.8% YoY

$-78.3MFY 2025

FY21 $-84.4MFY22 $-41.7MFY24 $-35.1MFY25 $-78.3M

Operating Income

-6.4% YoY

$-72.9MFY 2025

FY21 $-82.1MFY22 $-37.4MFY24 $-68.5MFY25 $-72.9M

EPS (Diluted)

+72.1% YoY

$-5.84FY 2025

FY21 —FY22 $-3.16FY24 $-20.91FY25 $-5.84

Total Assets

-22.7% YoY

$116.5MFY 2025

FY21 $80.2MFY22 $33.4MFY24 $150.7MFY25 $116.5M

Op. Cash Flow

-4.9% YoY

$-51.5MFY 2025

FY21 $-70.9MFY22 $-26.8MFY24 $-49.1MFY25 $-51.5M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$59.0K -86.6%	$441.0K -97.6%	$18.1M +234.4%	$5.4M -19.4%	$6.7M -0.8%	$6.8M
Net Income	$-78.3M -122.8%	$-35.1M +15.7%	$-41.7M +50.6%	$-84.4M -32.9%	$-63.5M -295.1%	$-16.1M
Operating Income	$-72.9M -6.4%	$-68.5M -83.0%	$-37.4M +54.4%	$-82.1M -12.8%	$-72.8M -351.4%	$-16.1M
EPS (Diluted)	$-5.84 +72.1%	$-20.91 -560.9%	$-3.16	—	—	—
Total Assets	$116.5M -22.7%	$150.7M +351.7%	$33.4M -58.4%	$80.2M +83.3%	$43.8M +21.2%	$36.1M
Operating Cash Flow	$-51.5M -4.9%	$-49.1M -83.4%	$-26.8M +62.3%	$-70.9M -74.9%	$-40.5M -111.9%	$-19.1M

AI Insight: AVTX Financial Trends

Avalo is a pre-revenue biotech burning cash with no inflection in sight; equity has eroded 50% as operating losses deepened.

• Revenue remains at or near $0M across all eight quarters; company has generated no commercial traction.

• Operating losses widened from $10M (Q2 2024) to $21M (Q1 2026), reflecting intensifying R&D and operational spend.

• Equity declined 52% from $133M (Q4 2024) to $68M (Q1 2026) as cumulative net losses eroded the balance sheet.

⚠ Operating cash burn accelerated to $18M in Q1 2026—highest in the dataset—signaling potential runway depletion risk.

⚠ No material licensing, partnership, or milestone revenue visible; clinical progress or regulatory approvals not reflected in financials.

AI Insight: AVTX Ratio Trends

Avalo remains deeply unprofitable with ROIC deteriorating through 2025, signaling ongoing cash burn and negative returns on invested capital.

• ROA swung from +93.6% in Q3 2024 to -78.6% in Q1 2026, indicating severe and persistent losses.

• ROIC collapsed from -40.0% in Q4 2024 to -95.1% in Q4 2025, the worst recorded quarter.

• ROE deteriorated to -114.9% in Q1 2026 from -66.1% in Q4 2025, showing worsening shareholder value destruction.

⚠ No operating margin, net profit margin, or leverage data reported—limits visibility into cost structure and capital efficiency.

⚠ Persistent negative returns across all profitability metrics suggest company is not yet generating sustainable earnings or cash generation.

Get alerted when AVTX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Avalo Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AVTX

FMR LLC
$43.0M2,879,481 sh
Caligan Partners LP
$24.4M1,635,023 sh
BVF INC/IL
$24.4M1,632,845 sh
Avoro Capital Advisors LLC
$21.1M1,410,000 sh
Affinity Asset Advisors, LLC
$20.0M1,340,840 sh
Nantahala Capital Management, LLC
$18.4M1,235,000 sh
UBS Group AG
$17.0M1,141,980 sh
Logos Global Management LP
$14.9M1,000,000 sh
Point72 Asset Management, L.P.
$13.7M916,142 sh
FARALLON CAPITAL MANAGEMENT LLC
$13.7M916,000 sh

Fund	Value	Shares
FMR LLC	$43.0M	2,879,481
Caligan Partners LP	$24.4M	1,635,023
BVF INC/IL	$24.4M	1,632,845
Avoro Capital Advisors LLC	$21.1M	1,410,000
Affinity Asset Advisors, LLC	$20.0M	1,340,840
Nantahala Capital Management, LLC	$18.4M	1,235,000
UBS Group AG	$17.0M	1,141,980
Logos Global Management LP	$14.9M	1,000,000
Point72 Asset Management, L.P.	$13.7M	916,142
FARALLON CAPITAL MANAGEMENT LLC	$13.7M	916,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AVTX on your watchlist

Track score changes the day Avalo Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AVTX a good stock to buy?

13F Pro's AI-powered analysis of Avalo Therapeutics, Inc. (AVTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AVTX are available on the AVTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own AVTX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AVTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Avalo Therapeutics, Inc.'s investment landscape.